| Authors: |
Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: dshong@mdanderson.org., Bauer TM; Medical Oncology, Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, USA., Lee JJ; Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, USA., Dowlati A; Department of Medicine-Hematology and Oncology, UH Cleveland Medical Center, Cleveland, USA., Brose MS; Department of Otorhinolaryngology, University of Pennsylvania, Philadelphia, USA., Farago AF; Department of Medicine, Massachusetts General Hospital, Boston, USA., Taylor M; The Knight Cancer Institute, Oregon Health & Science University, Portland, USA., Shaw AT; Department of Medicine, Massachusetts General Hospital, Boston, USA., Montez S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA., Smith S; Loxo Oncology, South San Francisco, USA., Tuch BB; Loxo Oncology, South San Francisco, USA., Ebata K; Loxo Oncology, South San Francisco, USA., Cruickshank S; Loxo Oncology, South San Francisco, USA., Cox MC; Loxo Oncology, South San Francisco, USA., Burris HA 3rd; Medical Oncology, Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, USA., Doebele RC; Department of Medicine, University of Colorado Cancer Center, Aurora, USA. |
